Evolving targets for lipid-modifying therapy

EMBO Molecular Medicine

Volumn 6, Issue 10, 2014, Pages 1215-1230

  Do, Rose Q ^a   Nicholls, Stephen J ^b   Schwartz, Gregory G ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Atherosclerosis; Cholesterol; Lipoproteins; Triglycerides

Indexed keywords

ACYLTRANSFERASE INHIBITOR; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CELL NUCLEUS RECEPTOR; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DIACYLGLYCEROL ACYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LOW DENSITY LIPOPROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MIMETIC PEPTIDE; NICOTINIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHOLIPASE INHIBITOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; PROTEIN INHIBITOR; SQUALENE SYNTHASE; SQUALENE SYNTHASE INHIBITOR; THYROMIMETIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN A; LIPOPROTEIN TRIGLYCERIDE;

ABSORPTION; ATHEROGENESIS; CHOLESTEROL TRANSPORT; DRUG TARGETING; HUMAN; INFUSION; LIPOPROTEIN METABOLISM; META ANALYSIS (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; ANTAGONISTS AND INHIBITORS; ARTERIOSCLEROSIS; BIOLOGICAL MODEL; DRUG EFFECTS; LIPID METABOLISM; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; HUMANS; LIPID METABOLISM; LIPOPROTEIN(A); LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; TRIGLYCERIDES;

EID: 84908090526     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201404000     Document Type: Review

References (116)

1. Aalto-Setala K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL (1992) Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 90: 1889-1900
2. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse Jr. 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC et al (2010) Effects of combination Lipid therapy in type 2 diabetes mellitus. N Engl J Med 17: 1563-1574
3. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M (1996) Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271: 518-520
4. Akram ON, Bernier A, Petrides F, Wong G, Lambert G (2010) Beyond LDL cholesterol, a new role for PCSK9. Arterioscler Thromb Vasc Biol 30: 1279-1281
5. Angelin B, Kristensen JD, Eriksson M, Carlsson B, Klein I, Olsson AG, Chester Ridgway E, Ladenson PW (2014) Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome. J Intern Med. doi:10.1111/joim.12261
6. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278
7. Bailey D, Jahagirdar R, Gordon A, Hafiane A, Campbell S, Chatur S, Wagner GS, Hansen HC, Chiacchia FS, Johansson J et al (2010) RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol 55: 2580-2589
8. Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN (2012) Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 110: 984-992
9. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD et al (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109-2122
10. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM (2004) Antiinflammatory properties of HDL. Circ Res 95: 764-772
11. Besler C, Luscher TF, Landmesser U (2012) Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med 4: 251-268
12. Bielicki JK, Zhang H, Cortez Y, Zheng Y, Narayanaswami V, Patel A, Johansson J, Azhar S (2010) A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res 51: 1496-1503
13. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365: 2255-2267
14. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH (1992) Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 90: 52-60
15. Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P (2011) Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol 57: 267-272
16. Califf RM, Lokhnygina Y, Cannon CP, Stepanavage ME, McCabe CH, Musliner TA, Pasternak RC, Blazing MA, Giugliano RP, Harrington RA et al (2010) An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J 159: 705-709
17. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W (1986) Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8: 1245-1255
18. Cariou B, Hanf R, Lambert-Porcheron S, Zair Y, Sauvinet V, Noel B, Flet L, Vidal H, Staels B, Laville M (2013) Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 10: 2923-2930
19. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256: 2835-2838
20. Chen Z, Wang SP, Krsmanovic ML, Castro-Perez J, Gagen K, Mendoza V, Rosa R, Shah V, He T, Stout SJ et al (2012) Small molecule activation of lecithin cholesterol acyltransferase modulates lipoprotein metabolism in mice and hamsters. Metabolism 61: 470-481
21. Cho KH (2009) Synthesis of reconstituted high density lipoprotein (rHDL) containing apoA-I and apoC-III: the functional role of apoC-III in rHDL. Mol Cells 27: 291-297
22. Choi YJ, Roberts BK, Wang X, Geaney JC, Naim S, Wojnoonski K, Karpf DB, Krauss RM (2012) Effects of the PPAR-delta agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis 220: 470-476
23. Cordeiro A, Souza LL, Einicker-Lamas M, Pazos-Moura CC (2013) Non-classic thyroid hormone signalling involved in hepatic lipid metabolism. J Endocrinol 216: R47-R57
24. Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ (2005) An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 46: 872-884
25. Cuchel M, Meagher EA, du Toit TH, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, Gaudet D et al (2013) Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 381: 40-46
26. Cuchel M, Rader DJ (2013) Microsomal transfer protein inhibition in humans. Curr Opin Lipidol 24: 246-250
27. Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, Garber DW, Mishra VK, Epand RM, Epand RF, Lund-Katz S et al (2001) Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res 42: 1096-1104
28. Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, Isaacsohn J, Toth P, Burke SK (1999) Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 16: 1893-1900
29. Davignon J (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation 109(23 Suppl 1):III 39-43
30. Davignon J, Dubuc G, Seidah NG (2010) The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. Curr Atheroscler Rep 12: 308-315
31. Denison H, Nilsson C, Lofgren L, Himmelmann A, Martensson G, Knutsson M, Al-Shurbaii A, Tornqvist H, Eriksson JW (2014) Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes Obes Metab 4: 334-343
32. Di AE, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ et al (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302: 1993-2000
33. Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, Crispino CP, Smirnakis KV, Emery MG, Colbert A et al (2012) Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 60: 1888-1898
34. Do RQ, Vogel RA, Schwartz GG (2013) PCSK9 Inhibitors: potential in cardiovascular therapeutics. Curr Cardiol Rep 3: 345
35. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A (2004) Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 24: 1454-1459
36. Erqou S, Kaptoge S, Perry PL, Di AE, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302: 412-423
37. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif JC et al (2011) Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 378: 1547-1559
38. Fievet C, Staels B (2009) Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis. Biochem Pharmacol 77: 1316-1327
39. Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE et al (2008) Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 154: 1465-1473
40. Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R, Fan Y et al (2008) Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 105: 11915-11920
41. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V et al (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 20: 1237-1245
42. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA et al (2005) The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 102: 8132-8137
43. Goldberg IJ, Eckel RH, McPherson R (2011) Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol 31: 1716-1725
44. Gotto AM Jr, Cannon CP, Li XS, Vaidya S, Kher U, Brinton EA, Davidson M, Moon JE, Shah S, Dansky HM et al (2014) Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol 113: 76-83
45. Graham MJ, Lee RG, Bell TA III, Fu W, Mullick AE, Alexander VJ, Singleton W, Viney N, Geary R, Su J et al (2013) Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 112: 1479-1490
46. Gullberg H, Rudling M, Forrest D, Angelin B, Vennstrom B (2000) Thyroid hormone receptor beta-deficient mice show complete loss of the normal cholesterol 7alpha-hydroxylase (CYP7A) response to thyroid hormone but display enhanced resistance to dietary cholesterol. Mol Endocrinol 14: 1739-1749
47. Hafiane A, Jabor B, Ruel I, Ling J, Genest J (2014) High-density lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes. Am J Cardiol 113: 249-255
48. Hancock MA, Boffa MB, Marcovina SM, Nesheim ME, Koschinsky ML (2003) Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem 278: 23260-23269
49. Handattu SP, Nayyar G, Garber DW, Palgunachari MN, Monroe CE, Keenum TD, Mishra VK, Datta G, Anantharamaiah GM (2013) Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice. Atherosclerosis 227: 58-64
50. Hashimoto K, Yamada M, Matsumoto S, Monden T, Satoh T, Mori M (2006) Mouse sterol response element binding protein-1c gene expression is negatively regulated by thyroid hormone. Endocrinology 147: 4292-4302
51. van der Hoorn J, Linden D, Lindahl U, Bekkers M, Voskuilen M, Nilsson R, Oscarsson J, Lindstedt E, Princen H (2011) Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels. Br J Pharmacol 162: 1553-1563
52. Hurt-Camejo E, Camejo G, Peilot H, Oorni K, Kovanen P (2001) Phospholipase A(2) in vascular disease. Circ Res 89: 298-304
53. Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH, Tun P, Zupkis RV, Greguski RA (1994) Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 154: 1586-1595
54. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A (2014) Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 371: 32-41
55. Kamanna VS, Kashyap ML (2008) Mechanism of action of niacin. Am J Cardiol 8A: 20B-26B
56. Kappus MS, Murphy AJ, Abramowicz S, Ntonga V, Welch CL, Tall AR, Westerterp M (2014) Activation of liver X receptor decreases atherosclerosis in Ldlr/ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells. Arterioscler Thromb Vasc Biol 2: 279-284
57. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA et al (2008) Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 14: 1431-1443
58. Katz A, Udata C, Ott E, Hickey L, Burczynski ME, Burghart P, Vesterqvist O, Meng X (2009) Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J Clin Pharmacol 49: 643-649
59. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM (2006) Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 114: 681-687
60. Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, Baxter JD, Angelin B (2010) Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 362: 906-916
61. Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B (2011) Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 217: 492-498
62. Lee RG, Willingham MC, Davis MA, Skinner KA, Rudel LL (2000) Differential expression of ACAT1 and ACAT2 among cells within liver, intestine, kidney, and adrenal of nonhuman primates. J Lipid Res 41: 1991-2001
63. Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Maerz W, Lehmacher W, Heibges A et al (2013) Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 128: 2567-2576
64. Leon C, Hill JS, Wasan KM (2005) Potential role of acyl-coenzyme A:cholesterol transferase (ACAT) Inhibitors as hypolipidemic and antiatherosclerosis drugs. Pharm Res 22: 1578-1588
65. Lin JZ, Martagon AJ, Hsueh WA, Baxter JD, Gustafsson JA, Webb P, Phillips KJ (2012) Thyroid hormone receptor agonists reduce serum cholesterol independent of the LDL receptor. Endocrinology 153: 6136-6144
66. Lincoff A, Tardif J, Schwartz G, Nicholls S, Rydén L, Neal B, Malmberg K, Wedel H, Buse J, Henry R et al (2014) Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA 311: 1515-1525
67. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298: 1180-1188
68. Lipid Research Clinics Program (1984) The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 251: 351-364
69. Luc G, Bard JM, Arveiler D, Ferrieres J, Evans A, Amouyel P, Furchart JC, Ducimetiere P (2002) Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2: 377-384
70. Luscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Munzel T, Kastelein JJ, Deanfield JE (2012) Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 33: 857-865
71. Marquart TJ, Wu J, Lusis AJ, Baldan A (2013) Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 33: 455-458
72. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA (2012) Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 59: 2344-2353
73. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E (2008) Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 51: 724-730
74. Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE (2011a) Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 306: 2099-2109
75. Nicholls SJ, Chapman J, Ballantyne CM, Barter PJ, Brewer B, Kastelein JJ, Gordon A, Johansson J, Wong N, Puri R et al (2013) ASSURE: effect of an oral agent inducing apo A-I synthesis on progression of coronary atherosclerosis: results of the ASSURE study. Eur Soc Cardiol 365: 708 (Abstract)
76. Nicholls SJ, Dusting GJ, Cutri B, Bao S, Drummond GR, Rye KA, Barter PJ (2005) Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111: 1543-1550
77. Nicholls SJ, Gordon A, Johansson J, Wolski K, Ballantyne CM, Kastelein JJ, Taylor A, Borgman M, Nissen SE (2011b) Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol 57: 1111-1119
78. Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V et al (2014) Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 311: 252-262
79. Nishimoto T, Ishikawa E, Anayama H, Hamajyo H, Nagai H, Hirakata M, Tozawa R (2007) Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. Toxicol Appl Pharmacol 223: 39-45
80. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL et al (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290: 2292-2300
81. Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD et al (2006) Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 354: 1253-1263
82. Nohria A, Prsic A, Liu PY, Okamoto R, Creager MA, Selwyn A, Liao JK, Ganz P (2009) Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 2: 517-521
83. Ohshiro T, Tomoda H (2011) Isoform-specific inhibitors of ACATs: recent advances and promising developments. Future Med Chem 3: 2039-2061
84. Porez G, Prawitt J, Gross B, Staels B (2012) Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res 53: 1723-1737
85. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ, Fernandez-Hernando C (2010) MiR-33 contributes to the regulation of cholesterol homeostasis. Science 328: 1570-1573
86. Ritsch A, Scharnagl H, Eller P, Tancevski I, Duwensee K, Demetz E, Sandhofer A, Boehm BO, Winkelmann BR, Patsch Jr. et al (2010) Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 121: 366-374
87. Riwanto M, Rohrer L, Roschitzki B, Besler C, Mocharla P, Mueller M, Perisa D, Heinrich K, Altwegg L, von Eckardstein A et al (2013) Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 127: 891-904
88. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS (2012) Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 308: 1024-1033
89. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF et al (2001) Veterans affairs high-density lipoprotein intervention trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 12: 1585-1591
90. Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT, Schaefer EJ (2011) HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 57: 392-410
91. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA (2012) Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 20: 1891-1900
92. Rotllan N, Ramirez CM, Aryal B, Esau CC, Fernandez-Hernando C (2013) Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/- mice-brief report. Arterioscler Thromb Vasc Biol 33: 1973-1977
93. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA et al (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367: 2089-2099
94. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Botker HE et al (2008) Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118: 1172-1182
95. Shearer GC, Savinova OV, Harris WS (2012) Fish oil -- how does it reduce plasma triglycerides? Biochim Biophys Acta 5: 843-851
96. Sjouke B, Langslet G, Ceska R, Nicholls SJ, Nissen SE, Ohlander M, Ladenson PW, Olsson AG, Hovingh GK, Kastelein JJ (2014) Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Diabetes Endocrinol 6: 455-463
97. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Luscher TF, Noll G (2002) High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105: 1399-1402
98. STABILITY Investigators (2014) Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 370: 1702-1711
99. Stein EA, Bays H, O'Brien D, Pedicano J, Piper E, Spezzi A (2011) Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation 123: 1974-1985
100. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R et al (2012) Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 366: 1108-1118
101. Tadin-Strapps M, Peterson LB, Cumiskey AM, Rosa RL, Mendoza VH, Castro-Perez J, Puig O, Zhang L, Strapps WR, Yendluri S et al (2011) siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids. J Lipid Res 52: 1084-1097
102. Tardif JC, Ballantyne CM, Barter P, Dasseux JL, Fayad ZA, Guertin MC, Kastelein JJ, Keyserling C, Klepp H, Koenig W et al (2014) Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J doi: 10.1093/eurheartj/ehu171
103. Tardif JC, Gregoire J, L'Allier PL, Anderson TJ, Bertrand O, Reeves F, Title LM, Alfonso F, Schampaert E, Hassan A et al (2004) Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 110: 3372-3377
104. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA et al (2007) Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297: 1675-1682
105. Tardy C, Goffinet M, Boubekeur N, Ackermann R, Sy G, Bluteau A, Cholez G, Keyserling C, Lalwani N, Paolini JF et al (2014) CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis 1: 110-118
106. The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute (2014) Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 371: 22-31
107. Thomas TR, Ziogas G, Harris WS (1997) Influence of fitness status on very-low-density lipoprotein subfractions and lipoprotein(a) in men and women. Metabolism 46: 1178-1183
108. Thompson A, Di AE, Sarwar N, Erqou S, Saleheen D, Dullaart RP, Keavney B, Ye Z, Danesh J (2008) Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 299: 2777-2788
109. Vaughan AM, Oram JF (2006) ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL. J Lipid Res 47: 2433-2443
110. Viney N, Graham M, Crooke R, Hughes S, Singleton W, Isis Pharmaceuticals I (2013) Evaluation of Isis Apo(a)Rx, an antisense inhibitor to apolipoprotein(a) in healthy volunteers. Am Heart Asssoc 128: A14196
111. Visser ME, Wagener G, Baker BF, Geary RS, Donovan JM, Beuers UH, Nederveen AJ, Verheij J, Trip MD, Basart DC et al (2012) Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 33: 1142-1149
112. Waksman R, Torguson R, Kent KM, Pichard AD, Suddath WO, Satler LF, Martin BD, Perlman TJ, Maltais JA, Weissman NJ et al (2010) A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 55: 2727-2735
113. Wiesner P, Tafelmeier M, Chittka D, Choi SH, Zhang L, Byun YS, Almazan F, Yang X, Iqbal N, Chowdhury P et al (2013) MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. J Lipid Res 54: 1877-1883
114. Zannis VI, Koukos G, Drosatos K, Vezeridis A, Zanni EE, Kypreos KE, Chroni A (2008) Discrete roles of apoA-I and apoE in the biogenesis of HDL species: lessons learned from gene transfer studies in different mouse models. Ann Med 40(Suppl 1): 14-28
115. Zhao W, Du F, Zhang M, Sun S, Yu H, Fan D (2011) A new recombinant human apolipoprotein E mimetic peptide with high-density lipoprotein binding and function enhancing activity. Exp Biol Med (Maywood) 236: 1468-1476
116. Zhou Q, Liao JK (2010) Pleiotropic effects of statins: basic research and clinical perspectives. Circ J 5: 818-826